Ionis Pharmaceuticals (IONS) to Present Phase 2 Results of donidalorsen

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AZN
6. ROIV
7. AAPL
8. HOOD
9. QQQ
10. QCOM

Go back to Ionis Pharmaceuticals (IONS) to Present Phase 2 Results of donidalorsen

Ionis Pharmaceuticals (IONS) PT Lowered to $38 at Stifel, Following Earnings

November 4, 2021 11:45 AM EDT

Stifel analyst Paul Matteis lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $38.00 (from $42.00) while maintaining a Hold rating.

Analyst comments: "The stock continues to face headwinds after multiple set-backs including the recent miss in the ph3 study of BIIB-partnered... More

Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Needham & Company

November 4, 2021 7:28 AM EDT

Needham & Company analyst Chad Messer lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $84.00) while maintaining a Buy rating.

The analyst commented, "IONS reported 3Q21 financial results yesterday, and we spoke w/ mgmt for additional details. Partner BIIB (not rated) previously... More

Ionis Pharmaceuticals (IONS) PT Lowered to $33 at Barclays

November 4, 2021 4:56 AM EDT

Barclays analyst Gena Wang lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $33.00 (from $38.00) while maintaining a Equalweight rating.... More